Compare GIC & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIC | ATAI |
|---|---|---|
| Founded | 1949 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 1996 | 2021 |
| Metric | GIC | ATAI |
|---|---|---|
| Price | $31.46 | $4.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.57 |
| AVG Volume (30 Days) | 87.3K | ★ 4.2M |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 17.09 | N/A |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $1,379,100,000.00 | $308,000.00 |
| Revenue This Year | $5.72 | N/A |
| Revenue Next Year | $4.46 | $285.00 |
| P/E Ratio | $17.26 | ★ N/A |
| Revenue Growth | ★ 4.80 | N/A |
| 52 Week Low | $20.79 | $1.15 |
| 52 Week High | $38.53 | $6.73 |
| Indicator | GIC | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 56.68 |
| Support Level | $30.85 | $3.42 |
| Resistance Level | $31.85 | $4.46 |
| Average True Range (ATR) | 1.00 | 0.28 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 17.23 | 72.39 |
Global Industrial Co is a value-added industrial distributor. The company distributes a wide range of industrial and maintenance, repair, and operations (MRO) products to customers across North America, including storage and shelving, safety and security, carts and trucks, HVAC and fans, furniture and decor, material handling, janitorial and facility maintenance, workbenches and shop desks, tools and instruments, plumbing and pumps, office and school supplies, packaging and shipping, lighting and electrical, food service and retail, medical and laboratory, motors and power transmission, building supplies, machining, fasteners and hardware, vehicle maintenance, and raw materials.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.